Data / Form D filings / Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc.: Form D filings
Zikani Therapeutics, Inc., a pharmaceuticals company in Watertown, MA, filed 4 Form D notices with the SEC between 2015 and 2020. The latest, on April 16, 2020, reports $7.5 million sold of a $7.5 million offering to 4 investors.
Find out what Zikani Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 480 Arsenal St., Ste. 130, Watertown, MA, 02472
- Phone
- (617) 229-6503
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1634953
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 16, 2020 | New notice | $7,500,000 | $7,500,000 | $0 | 4 | Apr 1, 2020 | sec.gov |
| Mar 13, 2018 | New notice | $20,000,000 | $12,000,000 | $8,000,000 | 6 | Mar 1, 2018 | sec.gov |
| Apr 29, 2016 | Amendment | $27,800,000 | $12,176,000 | $15,624,000 | 10 | Feb 10, 2015 | sec.gov |
| Feb 25, 2015 | New notice | $22,300,000 | $8,160,000 | $14,140,000 | 8 | Feb 10, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Sumit Aggarwal | Executive Officer, Director | |
| Christopher A. Viehbacher | Director | |
| Raj B. Parekh, Ph.D. | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Apr 13, 2020 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Zikani Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.